More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Troglitazone [97322-87-7]
Chemical Structure
Chemical Structure
Chemical Structure

Troglitazone [97322-87-7]

Research Use Only
AG-CR1-3565
AdipoGen Life Sciences
CAS Number97322-87-7
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight441.5
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Troglitazone [97322-87-7]
  • Delivery Days Customer
    10
  • CAS Number
    97322-87-7
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Molecular Formula
    C24H27NO5S
  • Molecular Weight
    441.5
  • Scientific Description
    Chemical. CAS: 97322-87-7. Formula: C24H27NO5S. MW: 441.5. Potent and selective PPARgamma agonist with no activation of PPARalpha and PPARdelta. Anti-diabetic agent with potent glucose-lowering effects and decreasing insulin resistance in adipose tissues. Stimulates adipogenesis. Apoptosis and cell cycle arrest inducer in several cancer cell lines. Anti-inflammatory. Inhibits vascular smooth muscle cell (VSMC) migration. - Potent and selective PPARgamma agonist with no activation of PPARalpha and PPARdelta [2]. Anti-diabetic agent with potent glucose-lowering effects and decreasing insulin resistance in adipose tissues. Stimulates adipogenesis [1, 6, 8]. Apoptosis and cell cycle arrest inducer in several cancer cell lines [3-8]. Anti-inflammatory [8-10, 12]. Inhibits vascular smooth muscle cell (VSMC) migration [11].
  • SMILES
    CC1=C(C)C2=C(CCC(C)(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)O2)C(C)=C1O
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats: T. Fujiwara, et al.; Diabetes 37, 1549 (1988)
  • An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma): J.M. Lehmann, et al.; J. Biol. Chem. 270, 12953 (1995)
  • Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids: H. Asou, et al.; Int. J. Oncol. 15, 1027 (1999)
  • Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators: Y. Kodera, et al.; J. Biol. Chem. 275, 33201 (2000)
  • Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis: Y. Tsubouchi, et al.; BBRC 270, 400 (2000)
  • Troglitazone and related compounds: therapeutic potential beyond diabetes: T. Fujiwara & H. Horikoshi; Life Sci. 67, 2405 (2000)
  • Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells: T. Okura, et al.; Eur. J. Pharmacol. 407, 227 (2000)
  • Troglitazone and related compounds: therapeutic potential beyond diabetes: T. Fujiwara & H. Horikoshi; Life Sci. 67, 2405 (2000) (Review)
  • Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese: H. Ghanim, et al.; J. Clin. Endocrinol. Metab. 86, 1306 (2001)
  • Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: A. Aljada, et al.; evidence of an antiinflammatory action?: J. Clin. Endocrinol. Metab. 86, 3250 (2001)